presented

LINKIN PARK TO ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSILINKIN PARK TO ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI

LINKIN PARK TO ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI

Pepsi reveals the iconic global superstars will headline the UCL final's unmissable annual 'Kick Off Show'LINKIN PARK has composed and recorded…

1 week ago
Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADDupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…

2 months ago
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADPress Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…

2 months ago
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…

2 months ago
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in FibromyalgiaTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL…

2 months ago
Gulf Beverages presented and honored Dubai Duty Free with the Exclusive Rampur Signature Reserve, in the presence of Radico Khaitan TeamGulf Beverages presented and honored Dubai Duty Free with the Exclusive Rampur Signature Reserve, in the presence of Radico Khaitan Team

Gulf Beverages presented and honored Dubai Duty Free with the Exclusive Rampur Signature Reserve, in the presence of Radico Khaitan Team

NEW DELHI, Feb. 28, 2025 /PRNewswire/ -- Gulf Beverages proudly presented Dubai Duty Free (DDF) with an exclusive memento –…

2 months ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO ConferenceIO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

February 23, 2025 12:07 ET  | Source: IO Biotech • Findings support the development of a novel peptide vaccine targeting…

2 months ago
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis MeetingEYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…

2 months ago